

## **ASX RELEASE**

### **ADMEDUS EXPANDS CARDIOCEL® PORTFOLIO TO MEET SURGICAL NEEDS**

- New 2cm x 2cm CardioCel® bio-scaffold material for repair and reconstruction of congenital heart defects (CHD) released into market
- New 2cm x 2cm CardioCel® size developed as a result of feedback from surgeons
- CardioCel® now used in over 95 centres internationally

#### **Brisbane, Australia 3<sup>rd</sup> September, 2015**

Admedus Limited (ASX: AHZ) has today announced the development and release of a new 2cm x 2cm CardioCel® bio-scaffold material as part of the CardioCel® product line extension strategy.

The 2cm x 2cm CardioCel® bio-scaffold material is a line extension of the currently manufactured and commercially available 4cm x 4cm, 5cm x 8cm and 2cm x 8cm materials. The 2cm x 2cm sized bio-scaffold material was developed based on feedback from global congenital surgeons who felt the smaller scaffold could potentially be valuable across the spectrum of CHD repair and reconstruction procedures.

"The release of a 2cm x 2cm CardioCel® bio-scaffold is part of our continued strategy to offer a complete range of CardioCel® products for all cardiovascular repairs and reconstructions," said Admedus CEO Lee Rodne.

"We are excited to make the new size available to our key surgeons, as we work closely with them to advance the management of congenital heart defects internationally and offer patients the clinical benefits of the ADAPT® tissue engineering process," said Mr Rodne.

CardioCel® bio-scaffold materials are created using Admedus' ADAPT® tissue engineering process, where DNA and RNA is removed from animal pericardium tissue to create a collagen matrix used for treatment and repair within the body.

Earlier this year, Admedus shipped 2cm x 8cm CardioCel® bio-scaffold materials to the US for use in vascular repairs such as carotid endarterectomies.

“We believe the development of different sizes of the CardioCel® product perfectly demonstrates how the ADAPT® tissue engineering process can be tailored to meet market demand and provide multiple product revenue streams in the Company and drive sales growth. With CardioCel® now used in over 95 centres across the US, Canada, Asia, Australia and Europe, we will continue to investigate the development of additional regenerative tissue products across a range of surgical applications.”

The 2cm x 2cm CardioCel® bio-scaffold material will initially be released to global congenital surgery Key Opinion Leaders to gain further clinical experience of the material with a view to undertaking a broader commercial launch.

Follow us:

Twitter: @Admedus

Facebook: [www.facebook.com/pages/Admedus](http://www.facebook.com/pages/Admedus)

**For more information, please contact:**

Dr Julian Chick | Chief Operating Officer | Admedus Limited  
Tel: +61 (0)8 9266 0100

**Media:**

Shevaun Cooper | PR Manager | Admedus Limited  
Tel: +61 (0) 417 985 599 | Email: [scooper@admedus.com](mailto:scooper@admedus.com)

**Media Europe**

FTI Consulting  
Simon Conway / Victoria Foster Mitchell  
Tel: +44 (0) 20 3727 1000  
[admedus@fticonsulting.com](mailto:admedus@fticonsulting.com)

**About Admedus Limited**

Admedus (ASX: AHZ) is a specialist healthcare company. Our focus is on investing in and developing next generation technologies with world class partners, acquiring strategic assets to grow product and service offerings and expanding revenues from our existing, profitable medical sales and distribution business. The company has assets from research & development through clinical development as well as sales, marketing and distribution.

Admedus has commercialised its innovative tissue engineering technology for regenerative medicine in four continents. We also have a major interest in developing the next generation of vaccines with a Brisbane-based research

group led by Professor Ian Frazer. The vaccine programmes target disease with significant global potential, such as Herpes and Human Papillomavirus.

Further information on the company can be found on [www.admedus.com](http://www.admedus.com)

### **About CardioCel®**

CardioCel® is a type of cardiovascular bio-scaffold that can be used to repair congenital heart deformities and more complex heart defects. It is used to repair diseased paediatric and adult hearts. These repairs range from routine hole-in-the-heart operations to major vessel outflow tract repairs. The CardioCel® scaffold may also be used to repair heart valves. CardioCel® has been shown to allow tissue regeneration once implanted. Some researchers postulate that stem cells play an active role in tissue regeneration, suggesting that the product facilitates endogenous stem cells and other cells to regenerate and repair damaged tissue. CardioCel® is the Admedus Group's lead regenerative tissue bio-implant used in repairing heart defects, including the repair of heart valves. It is engineered via the Admedus Group's proprietary ADAPT® tissue engineering process to produce a durable, collagen scaffold with handling properties preferred by surgeons that avoids calcification, while supporting native cell infiltration, growth and differentiation.